{"id":"amp945-ascending-doses","_chembl":{"chemblId":"CHEMBL3689071","moleculeType":"Small molecule","molecularWeight":"527.59"},"modality":"Small molecule","_dailymed":null,"_scrapedAt":"2026-03-28T05:54:31.584Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123553,"model":"claude-sonnet-4-5-20250929"},"description":"AMP945 is an investigational small molecule drug candidate being developed by Amplia Therapeutics Limited. Currently in Phase 1 clinical trials with ascending dose evaluation, the compound's molecular target and therapeutic indication have not been publicly disclosed.","indications":{"approved":[{"status":"investigational","condition":"Unknown","patientPopulation":"Unknown"}]},"trialDetails":[{"nctId":"NCT05355298","phase":"PHASE1, PHASE2","title":"ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amplia Therapeutics Limited","startDate":"2022-05-31","conditions":"Pancreatic Cancer, PDAC, Pancreatic Ductal Adenocarcinoma","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":814,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AMP945 ascending doses","genericName":"AMP945 ascending doses","companyName":"Amplia Therapeutics Limited","companyId":"amplia-therapeutics-limited","firstApprovalDate":"","aiSummary":"AMP945 is a small molecule being studied in a Phase 1b/2a clinical trial (NCT05355298) for the treatment of pancreatic cancer, specifically Pancreatic Ductal Adenocarcinoma (PDAC). The trial involves ascending doses of AMP945 to determine its pharmacokinetics, safety, and efficacy in combination with nab-paclitaxel and gemcitabine.","enrichmentLevel":2,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}